Switching from tenofovir disoproxil fumarate (tdf) and/or other oral antivirals (oavs) to tenofovir alafenamide (taf) in virally suppressed chronic hepatitis b (chb) patients with moderate or severe renal impairment, or with end-stage renal disease (esrd)
Recommended Citation
Janssen HL, Lampertico P, Chen C, Heo J, Fournier C, Ahn S, Tsang TY, Coffin CS, Huang Y, Marchesini G, Hui AJ, Elkhashab M, Jafri S, Chan CY, Tan SK, Zhao Y, Suri V, Flaherty JF, Gaggar A, Brainard D, Chuang W, Agarwal K, Gane E, Lim Y. Switching from tenofovir disoproxil fumarate (tdf) and/or other oral antivirals (oavs) to tenofovir alafenamide (taf) in virally suppressed chronic hepatitis b (chb) patients with moderate or severe renal impairment, or with end-stage renal disease (esrd). Gut 2021; 70(SUPPL 2):A76-A77.
Document Type
Conference Proceeding
Publication Date
9-1-2021
Publication Title
Gut
Abstract
Background We have previously shown in renally impaired (RI) CHB patients, including those with ESRD on HD, that switching to TAF from TDF and/or other OAVs maintains high rates of viral suppression with stable bone and renal safety parameters at Week 48. Here we present the final Week 96 results. Methods In this study, virally suppressed CHB patients (HBV DNA
PubMed ID
Not assigned.
Volume
70
Issue
SUPPL 2
First Page
A76
Last Page
A77
